Market open

Ultragenyx Pharmaceutical/RARE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ticker

RARE
Trading on

Industry

Biotechnology

Employees

1,276

RARE Metrics

BasicAdvanced
$4.8B
Market cap
-
P/E ratio
-$7.23
EPS
0.56
Beta
-
Dividend rate
$4.8B
0.56
$58.73
$31.52
631K
3.535
3.196
200.708
664.585
-8.22%
-23.42%
-208.43%
8.817
11.16
21.77
-8.617
19.47%
-29.42%
10.23%
10.18%

What the Analysts think about RARE

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.

RARE Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RARE Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy RARE

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical (RARE) has a market cap of $4.8B as of October 08, 2024.

What is the P/E ratio for Ultragenyx Pharmaceutical stock?

The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of October 08, 2024.

Does Ultragenyx Pharmaceutical stock pay dividends?

No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of October 08, 2024.

When is the next Ultragenyx Pharmaceutical dividend payment date?

Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.

What is the beta indicator for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.